The ISSCR 2024 Annual Meeting in Hamburg, Germany 10-13 July promises to showcase some of the most compelling discoveries of the year and drive meaningful conversations around those advances that are yielding new insights and accelerating progress. This year’s ISSCR has been said to be the most clinically focused to date. One of the sessions that was also quite interesting to me was the session called “Translation of Academic Research: From Nice to Have to Clinical Imperative” which addressed the complex challenges of moving advanced therapies from the lab to the clinic. A significant concern highlighted was the fragile state of Advanced Therapy Medicinal Products (ATMPs) in the EU, where 10 out of 26 approved therapies have already been withdrawn, according to the 2024 EMA CAT report. Despite these setbacks, the majority of these therapies originated from academic research before reaching the market through commercial entities.
https://haapaniemilab.org/events-and-appearances/the-international-society-for-stem-cell-research-isscr-annual-meeting-2024/
